Logo Logo
Help
Contact
Switch Language to German

Rataj, Felicitas; Jacobi, Severin J.; Stoiber, Stefan; Asang, Florian; Ogonek, Justyna; Tokarew, Nicholas; Cadilha, Bruno L.; van Puijenbroek, Erwin; Heise, Constanze; Duewell, Peter; Endres, Stefan; Klein, Christian and Kobold, Sebastian (2019): High-affinity CD16-polymorphism and Fc-engineered antibodies enable activity of CD16-chimeric antigen receptor-modified T cells for cancer therapy. In: British Journal of Cancer, Vol. 120, No. 1: pp. 79-87

Full text not available from 'Open Access LMU'.

Abstract

BACKGROUND: CD16-chimeric antigen receptors (CAR) T cells recognise the Fc-portion of therapeutic antibodies, which can enable the selective targeting of different antigens. Limited evidence exists as to which CD16-CAR design and antibody partner might be most effective. We have hypothesised that the use of high-affinity CD16 variants, with increased Fc-terminus antibody affinity, combined with Fc-engineered antibodies, would provide superior CD16-CAR T cell efficacy. METHODS: CD16-CAR T (wild-type or variants) cells were co-cultured with Panc-1 pancreatic cancer, Raji lymphoma or A375 melanoma cells in the presence or absence of anti-CD20, anti-MCSP, wild-type or the glycoengineered antibody variants. The endpoints were proliferation, activation, and cytotoxicity in vitro. RESULTS: The CD16 158 V variant of CD16-CAR T cells showed increased cytotoxic activity against all the tested cancer cells in the presence of the wild-type antibody directed against MCSP or CD20. Glycoengineered antibodies enhanced CD16-CAR T cell activity irrespective of CD16 polymorphisms as compared with the wild-type antibody. The combination of the glycoengineered antibodies with the CD16-CAR 158V variant synergised as seen by the increase in all endpoints. CONCLUSION: These results indicate that CD16-CAR with the high-affinity CD16 variant 158V, combined with Fc-engineered antibodies, have high anti-tumour efficacy.

Actions (login required)

View Item View Item